<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01251341</url>
  </required_header>
  <id_info>
    <org_study_id>5R01AT004698</org_study_id>
    <nct_id>NCT01251341</nct_id>
  </id_info>
  <brief_title>The Compassion and Attention Longitudinal Meditation Study</brief_title>
  <acronym>CALM</acronym>
  <official_title>Mechanisms of Meditation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arizona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The increasingly widespread use of meditation for stress-related emotional and medical&#xD;
      conditions highlights the urgent need to rigorously evaluate mechanisms through which the&#xD;
      benefits of practice might be conferred. Primary challenges in this regard include evaluating&#xD;
      dose response relationships between practice time and outcomes; clarifying whether&#xD;
      physiological and behavioral effects of meditation derive primarily from non-specific aspects&#xD;
      of training or result from specific meditation practices; and identifying molecular&#xD;
      mechanisms by which meditation might affect physiological responses relevant to&#xD;
      stress-related illness. Recent findings from a cross-sectional study by our group indicate&#xD;
      that young adults who are randomized to, and practice, compassion meditation demonstrate&#xD;
      reduced inflammatory responses, less emotional distress, and reduced autonomic responses to a&#xD;
      standardized laboratory psychosocial stressor (Trier Social Stress Test [TSST]) when compared&#xD;
      to subjects randomized to an active control condition. However, as a result of the&#xD;
      cross-sectional study design and lack of a meditation comparator arm, these results provide&#xD;
      only partial insight into key issues outlined above regarding the role played by specific&#xD;
      meditation procedures and/or practice time in observed physiological and behavioral outcomes.&#xD;
      The primary hypothesis of the proposed work is that practicing a meditation procedure&#xD;
      specifically designed to enhance empathic concern for others (i.e. compassion meditation)&#xD;
      will optimize autonomic reactivity to psychosocial stress in a manner that results in&#xD;
      diminished activation of peripheral inflammatory signaling pathways and reduced behavioral&#xD;
      distress.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of compassion meditation on inflammatory and behavioral responses to psychosocial stress using a longitudinal design.</measure>
    <time_frame>Five years</time_frame>
    <description>Innate immune cytokine responses will be assessed before and after a psychosocial stressor to evaluate the differential impact of the two interventions and the active control.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">226</enrollment>
  <condition>Immune System Processes</condition>
  <condition>Inflammatory Activation and Modulation</condition>
  <condition>ANS Function</condition>
  <arm_group>
    <arm_group_label>Compassion Meditation Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Health Education and Wellness Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mindful Attention Training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive-Based Compassion Training</intervention_name>
    <description>Eight-week training in compassion meditation, using a protocol developed by Geshe Lobsang Negi, Ph.D. of Emory University</description>
    <arm_group_label>Compassion Meditation Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Mindful Attention Training</intervention_name>
    <description>Eight week training in mindful attention, using a protocol developed by B. Alan Wallace, Ph.D.</description>
    <arm_group_label>Mindful Attention Training</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Adult Health Education Curriculum</intervention_name>
    <description>Eight week training in health and wellness, using a curriculum developed specifically for this study.</description>
    <arm_group_label>Health Education and Wellness Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Good medical health&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  current major depression&#xD;
&#xD;
          -  current substance abuse&#xD;
&#xD;
          -  lifetime history of schizophrenia or bipolar disorder type I as assessed by the&#xD;
             Structured Diagnostic Interview for DSM-IV (SCID)&#xD;
&#xD;
          -  suicidal ideation or suicide attempt within one year of study enrollment&#xD;
&#xD;
          -  diagnosis of any serious ongoing medical condition including malignancy, auto-immune&#xD;
             disease (i.e. rheumatoid arthritis, multiple sclerosis, Crohn's disease),&#xD;
             cardiovascular disease (other than hypertension), seizure disorder, endocrinopathy,&#xD;
             chronic infection (i.e. human immunodeficiency virus, hepatitis B or C), renal or&#xD;
             hepatic insufficiency, or any other current or past medical or psychiatric condition&#xD;
             that might increase the risk of study participation in the opinion of study personnel&#xD;
&#xD;
          -  treatment with psychotropic medications within the last year (i.e. antidepressants,&#xD;
             anxiolytics, psychostimulants or mood stabilizers)&#xD;
&#xD;
          -  active ongoing psychiatric treatment at the time of enrollment.&#xD;
&#xD;
          -  use of any psychotropic medication (i.e. antidepressants, anxiolytics,&#xD;
             psychostimulants or mood stabilizers) within one year of screening.&#xD;
&#xD;
          -  chronic use of anti-inflammatory/immunosuppressive agents, including, but not limited&#xD;
             to, aspirin, non-steroidal anti-inflammatory agents, COX-2 inhibitors,&#xD;
             corticosteroids, etanercept, infliximab, adalimumab or methotrexate.&#xD;
&#xD;
          -  any significant past meditation training/experience (defined as meditating more than 3&#xD;
             times a week for a period longer than a month)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Raison, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arizona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lobsang Tenzin Negi, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>November 30, 2010</study_first_submitted>
  <study_first_submitted_qc>November 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2010</study_first_posted>
  <last_update_submitted>December 4, 2014</last_update_submitted>
  <last_update_submitted_qc>December 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>inflammation</keyword>
  <keyword>immune system</keyword>
  <keyword>cytokines</keyword>
  <keyword>meditation</keyword>
  <keyword>compassion</keyword>
  <keyword>attention</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

